State of Wyoming Takes $819,000 Position in Celcuity, Inc. $CELC

State of Wyoming purchased a new position in shares of Celcuity, Inc. (NASDAQ:CELC) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 7,825 shares of the company’s stock, valued at approximately $819,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. EverSource Wealth Advisors LLC grew its stake in Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after acquiring an additional 319 shares during the last quarter. US Bancorp DE increased its holdings in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares in the last quarter. Parallel Advisors LLC acquired a new position in Celcuity during the first quarter worth about $38,000. Finally, Meeder Asset Management Inc. acquired a new position in Celcuity during the fourth quarter worth about $42,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

Celcuity Price Performance

Celcuity stock opened at $92.00 on Friday. The stock has a market capitalization of $4.49 billion, a P/E ratio of -21.40 and a beta of 0.20. Celcuity, Inc. has a 12-month low of $44.42 and a 12-month high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The firm’s 50-day moving average is $93.88 and its two-hundred day moving average is $108.45.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Equities analysts predict that Celcuity, Inc. will post -3.76 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Weiss Ratings raised shares of Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Stifel Nicolaus dropped their price objective on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research note on Friday. Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a research report on Saturday. HC Wainwright reaffirmed a “buy” rating and issued a $155.00 target price on shares of Celcuity in a research note on Friday. Finally, Citizens Jmp increased their target price on Celcuity from $160.00 to $177.00 and gave the company a “market outperform” rating in a report on Wednesday, July 15th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $153.64.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.